$TLPH

TALPHERA, INC.

Talphera is a specialty pharmaceutical company focused on developing and commercializing therapies for medically supervised settings. Its portfolio centers on Niyad, a nafamostat product candidate designed as a regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy in adult patients. Niyad is being studied in a registrational trial under an investigational device exemption. Talphera’s other nafamostat candidate, LTX-608, is formulated for direct intravenous infusion and is being explored for indications including disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis and antiviral treatment. The company has also explored pre-filled syringe candidates, including Fedsyra and phenylephrine, and is evaluating whether to discontinue them. Talphera’s strategy focuses on developing, obtaining approval for and commercializing Niyad, with plans to expand its portfolio of acute care therapies. Its sales and marketing resources support Niyad pre-launch activities, and it is evaluating whether to launch with internal resources or a commercial partner. It relies on contract manufacturers for Niyad development batches and would use them for commercial supply if approved. Talphera is headquartered in San Mateo, California.

No enriched coverage for $TLPH in the last 7 days.

No SEC Form 4 filings for $TLPH in the last 30 days.

See all $TLPH insider activity →
Med

What Talphera (TLPH) Said on Its Q3 Earnings Call

Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.

Talphera Q3 2026 Earnings Preview (NASDAQ:TLPH)

Talphera (TLPH) will report Q3 2026 earnings on November 12th. Analysts expect an EPS of -$0.06. The company has beaten EPS estimates 75% of the time in the past year, with 1 recent upward revision.

TLPH sentiment & insider activity

Recent TLPH coverage spans earnings, financial news and technology.

What's driving TLPH

AlphAI scores every news story that mentions TLPH with an AI model for sentiment and relevance, and aggregates insider trades from TALPHERA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TLPH

Score

What Talphera (TLPH) Said on Its Q3 Earnings Call

Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.

$TLPHMedAI 8/10

Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50

$TLPHMedEarnings

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi

$TLPHLowShareholder vote

TALPHERA, INC. (TLPH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_979677.htm EXHIBIT 10.1 ex_979677.htm Exhibit 10.1 AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN Originally Adopted by the Board of Directors: April 16, 2020 Originally Approved by the Stockholders: June 16, 2020 Amendment and Restatement Approved by the Board of D

Talphera Cuts Expenses 14 Percent

Talphera ( NASDAQ:TLPH ) , a specialty pharmaceutical company developing therapies for medically supervised hospital settings, reported its second quarter 2025 results on August 14, 2025. The company posted an EPS loss of $0.10 ( GAAP ) , which was better than the analyst consensus estimate of a ...

Talphera Cuts Costs and Speeds Trial

Talphera ( NASDAQ:TLPH ) reported second quarter 2025 results on August 14, 2025, highlighting accelerated clinical trial enrollment and a reduction in annual cash operating expense guidance to $16 million-$17 million for 2025.

Related tickers